Human immunoglobulin preparations for intravenous or subcutaneous administration are
the cornerstone of treatment in patients with primary immunodeficiency diseases affecting …

Adoptive immunotherapy using B-cell–targeted chimeric antigen receptor (CAR)-modified T
cells to treat hematologic malignancies is transforming cancer care for patients with …

Secondary hypogammaglobulinemia (SHG) is characterized by reduced immunoglobulin
levels due to acquired causes of decreased antibody production or increased antibody loss …

Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in the Western world
with an incidence of 4.2/100 000/year. The incidence increases to more than 30/100 …

Introduction The unprecedented success of chimeric antigen receptor (CAR)-T-cell therapy
in the management of B-cell malignancies comes with a price of specific side effects …

T cell engagers (TCE) such as chimeric antigen receptor (CAR) T cell therapy and bispecific
antibodies (BiAbs) for the treatment of multiple myeloma (MM) have significantly improved …

Idecabtagene vicleucel (ide-cel), a novel chimeric antigen receptor (CAR) T-cell therapy
targeting B-cell maturation antigen (BCMA), has recently gained approval by the US FDA for …

The article provides information on diagnosis and management of chronic lymphocytic
leukemia (CLL). It informs about diagnosis of the CLL which includes lymphocyte …

During the last few years, several new drugs have been introduced for treatment of patients
with multiple myeloma, which have significantly improved treatment outcome. All of these …

BACKGROUND Little is known about pathogen-specific humoral immunity after chimeric
antigen receptor–modified T (CAR-T) cell therapy for B cell malignancies. METHODS We …